SLTTF yields 10840.11% · JNJ yields 2.13%● Live data
📍 SLTTF pulled ahead of the other in Year 1
Combined, SLTTF + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of SLTTF + JNJ for your $10,000?
The REIT is an unincorporated, open-ended real estate investment trust governed by the laws of the Province of Ontario pursuant to an amended and restated Declaration of Trust dated as of December 31, 2024, as it may be further amended, supplemented or amended and restated from time to time (the "Declaration of Trust"). The REIT's portfolio consists of 46 commercial properties located in Canada, the United States, and Ireland. The units of the REIT trade on the Toronto Stock Exchange (TSX) under the symbol RPR.UN. On December 27, 2024, the TSX approved a 90-day extension of the remedial delisting review for the REIT, following an initial 120-day review period that began on July 4, 2024 and a subsequent 60-day extension. The review was a response to the REIT's financial condition. The extension was granted based on materials submitted by the REIT in relation to the REIT's plan and activities to restructure the majority of its debt. During this period, the REIT addressed these issues to meet the TSX's requirements. The trading of the REIT's securities was not impacted during the review process. Subsequent to March 31, 2025, the TSX lifted the delisting review. The principal and head office of the REIT is 130 Adelaide St W, Suite 3401, Toronto, Ontario, Canada, M5H 3P5. The registered office of the REIT is 100 King Street West, Suite 3400, Toronto, Ontario, Canada, M5X 1A4.
Full SLTTF Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.